Table 1.

Baseline patient characteristics and efficacy of gefitinib

CharacteristicNo. patients (N = 69)%
Sex
    Male3956.5
    Female3043.5
Age, median years (range)59 (30-82)
    Male57 (40-82)
    Female60 (30-67)
Stage
    IIIB34.3
    IV6695.7
ECOG performance status
    0-13956.5
    2-33043.5
Histology
    Adenocarcinoma4362.3
    Bronchioloalveolar carcinoma913.0
    Squamous cell carcinoma1420.3
    Others34.3
Smoking history
    Never smoked3550.7
    Smoked3449.3
Source of tissue
    Surgical resection2942.0
    Needle biopsy2333.3
    Bronchoscopic biopsy68.7
    Biopsy from metastatic site*1115.9
Efficacy of gefitinib


Best overall response
n
% (95% CI)
    Partial response1623.2 (13.2-33.2)
    Stable disease1826.1 (15.7-36.5)
    Progressive disease3550.7 (38.9-62.5)
Survival (mo)mn (95% CI)
    Time-to-progression2.6 (1.6-3.5)
    Overall survival10.3 (5.2-15.5)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • * Metastatic sites include four lymph nodes, three bones, two brains, one liver, and one pleura.